Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
OBJECTIVE
The validity of genotype:phenotype correlation studies in human hypertrophic cardiomyopathy (HCM) has recently been questioned, yet animal models and in vitro studies suggest distinct effects for different mutations. The aims of this study were to investigate whether distinct HCM-mutations have different consequences for cardiac structure and function in the absence of the confounding effects of hypertrophy.


RESULTS
Individuals aged 20-65 belonging to 21 R92W(TNNT2), R403W(MYH7), or A797T(MYH7) mutation-bearing families were investigated with 2D, M-mode, and Doppler echocardiography. Cardiac structural and functional parameters were compared between prehypertrophic mutation-carriers and their non-carrier family members, with concomitant adjustment for appropriate covariates. Findings were evaluated against existing animal and in vitro functional data. The distinct functional effect of the R92W(TNNT) mutation was a relative increase in systolic functional parameters, that of the A797T(MYH7) mutation was reduced diastolic function, while the R403W(MYH7) mutation reduced both systolic and diastolic function. The observed early effects of the R92W(TNNT2) mutation mechanistically fit with prolonged force-transients precipitated by increased Ca(2+) sensitivity of the thin filament, and that of the MYH7 mutations with local ATP depletion.


CONCLUSIONS
Evaluation of the impact of the mutations on cardiac structure and function in prehypertrophic mutation-carriers, relative to the baseline norm provided by their non-carrier family members, best recapitulated existing animal and in vitro functional data, while inclusion of mutation-carriers with hypertrophy obscured such findings. The results prompt speculation that timely treatment aimed at ameliorating Ca(2+) sensitivity for R92W(TNNT2)-carriers, and energy depletion for MYH7 mutation-carriers, may offer a plausible approach for preventing progression from a preclinical into a decompensated state.
Revera
Miriam
M
Department of Cardiology, IRCCS San Matteo Hospital, Pavia, Italy.
van der Merwe
Lize
L
Heradien
Marshall
M
Goosen
Althea
A
Corfield
Valerie A
VA
Brink
Paul A
PA
Moolman-Smook
Johanna C
JC
D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D000818:Animals; D020013:Calcium Signaling; D024722:Cardiac Myosins / Q000235:genetics*; D002312:Cardiomyopathy, Hypertrophic / Q000000981:diagnostic imaging / Q000235:genetics* / Q000503:physiopathology; D015150:Echocardiography, Doppler; D005260:Female; D005838:Genotype; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D053580:Muscle Strength; D009154:Mutation; D009200:Myocardial Contraction / Q000235:genetics*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D018995:Myosin Heavy Chains / Q000235:genetics*; D010641:Phenotype; D020107:Troponin T / Q000235:genetics*; D016277:Ventricular Function, Left / Q000235:genetics*
C501641:MYH7 protein, human; D020107:Troponin T; D000255:Adenosine Triphosphate; D024722:Cardiac Myosins; D018995:Myosin Heavy Chains